Anna-Barbara Moscicki, MDChief, Adolescent Medicine; Professor of Pediatrics, David Geffen School of Medicine at UCLA
Dr. Moscicki is Professor of Pediatrics at UCLA, Division Chief of Adolescent Medicine, Dr. Moscicki’s career has focused on adolescent gynecology and STI research with a specific focus in Human Papillomavirus, HIV infection and mucosal immunology. She trained in STI epidemiology and mucosal immunology. Dr. Moscicki has been the PI of a natural history study of HPV in adolescents and young women since 1990, one of the longest running HPV cohorts of which she was awarded an NIH MERIT. She has over 200,000 stored specimens from this cohort including cervical lavages, cervical biopsies, anal swabs, oral gargles, serum and blood clots. She serves on numerous national and international committees, including the W.H.O., N.I.H., American Society for Colposcopy and Cervical Pathology, and the American Cancer Society. Her work was influential in forming the new cervical cancer screening guidelines and triage of abnormal cytology in young women. She is also involved in health outcomes in perinatally HIV infected children including sexual risk behaviors, substance use, oral health, microbiomes, and HPV.
She has been involved in HIV research for over 20 years including member of the Adolescent Medicine HIV/AIDS Research Network, Adolescent Therapeutic Network , IMPAACT and PHACS. In PHACS, she is a member of the scientific Leadership Group, and co-chair of the Adolescent Working Group and co-PI of the Oral Health study in PHACS which focuses on the role of the microbiome in oral health.
Relevant Recent Publications
- Daud, II, Scott ME, Ma Y, Shiboski S, Farhat S, Moscicki AB. Association between toll-like receptors expression and human papillomavirus type 16 persistence. Int J Cancer 2011;128(4):879-86.
- Hwang LY, Scott M, Ma Y, Moscicki AB. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. Journal of Reproductive Immunology 2011; 88:66-71.
- Moscicki AB, Kaul R, Ma Y, Scott ME, Daud, II, Bukusi EA, Shiboski S, Rebbapragada A, Huibner S, Cohen CR. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J Acquir Immune Defic Syndr 2012;59(2):134-140.
- Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer III WA, Bryan J, Levin MJ for the IMPAACT/PACTG P1047 team. Humoral, mucosal and cell-mediated immunity against vaccine and non-vaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. Journal of Infectious Diseases. 2012; 206(8):1309-1318.
- Scott ME, Shvetsov YB, Thompson PJ, Hernandez BY, Zhu X, Wilkens LR, Killeen J, Vo D, Moscicki AB, Goodman MT. Cervical Cytokines and Clearance of Incident Human Papillomavirus Infection: Hawaii HPV Cohort Study. International Journal of Cancer. 2013; 133(5):1187-96.
- Moscicki AB, Ma Y, Farhat S, Jay J, Hanson E, Benningfield S, Jonte J, Godwin-Medina C, Wilson R, Shiboski S. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. Clin Infect Dis 2014;58(6):804-11
- Scott ME, Ma Y, Farhat S, Moscicki AB. Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response. Int J Cancer. Oct 23 2014. [e-pub ahead of print]
Active Funding in Microbiome-Related Research
|Funding Agency/Grant Number:||NIH NCI R37CA051323-26|
|Title:||“Natural history of HPV”|
|Funding Agency/Grant Number:||NIH NICHD U01 HD052102|
|Title:||“Oral Health in Perinatally HIV infected adolescents”|